Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Harrow Ip LLC is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, ensuring that each matter is reviewed by a different official. The portfolio's activity spans 3 distinct art units, indicating a range of technical focuses within their pharmaceutical filings. This distribution across 3 distinct art units requires the applicant to address different technical standards while resolving these 5 pending office actions. Practitioners should be prepared to manage the varying procedural norms of the 3 distinct art units involved.
The busiest examiner, GREENE, IVAN A, is responsible for 1 pending office action. With 5 distinct examiners for the 5 total pending actions, the company's workload is perfectly distributed among different officials. This arrangement provides 5 unique perspectives on the company's biotechnology claims across the 3 distinct art units. Practitioners should be prepared to manage 5 separate examiner interactions and the individual styles of each official. The 5 pending office actions represent a diverse and decentralized effort to protect the company's pharmaceutical intellectual property. This structure ensures that no single examiner's decision dominates the overall portfolio, allowing for independent evaluations of each biotechnology filing across the 3 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (33%) |
| §103 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GREENE, IVAN A | 1 | 18.7% | +6.4% |
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| PACKARD, BENJAMIN J | 1 | 66.7% | +15.6% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| BOATENG, AFUA BAMFOAA | 1 | 46.6% | +64.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844789 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | GREENE, IVAN A | — |
| 18390923 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629882 | TOPICAL OCULAR THERAPY | PACKARD, BENJAMIN J | 10d overdue |
| 18816461 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | RAO, SAVITHA M | — |
| 18390923 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KWON, YONG SOK | — |
| 18537780 | CORNEAL THERAPY | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18117126 | OPHTHALMIC DYE COMPOSITION AND METHOD FOR ADMINISTERING SAME | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1613 | 1 |
| 1691 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844789 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | GREENE, IVAN A | — | §101§103§112Other | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18816461 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ANESTHESIOLOGICAL APPLICATIONS | RAO, SAVITHA M | — | §103DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18629882 | TOPICAL OCULAR THERAPY | PACKARD, BENJAMIN J | 1612 | §103Other | Final Rejection | 10d overdue | Pending | Apr 08, 2024 |
| 18390923 | MIDAZOLAM AND KETAMINE FOR ENHANCED SEDATION | KWON, YONG SOK | 1613 | §101§102§103DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18537780 | CORNEAL THERAPY | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103§112DP | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18117126 | OPHTHALMIC DYE COMPOSITION AND METHOD FOR ADMINISTERING SAME | BOATENG, AFUA BAMFOAA | 1617 | §103DP | Final Rejection | — | Pending | Mar 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial